BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Biotie, UCB deal

Biotie said that UCB confirmed that it will not exercise an option for nitisinone ( SYN118) after reviewing data from a Phase IIa trial showing that the compound did not significantly improve motor function in patients with advanced Parkinson's disease. Upon reporting the data in...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >